<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957929</url>
  </required_header>
  <id_info>
    <org_study_id>APX001-102</org_study_id>
    <nct_id>NCT02957929</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amplyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amplyx Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase l double-blind, placebo-controlled, randomized study to investigate the
      safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of
      APX001 administered intravenously and orally, followed by an evaluation of the safety,
      tolerability, pharmacokinetics and drug-drug interaction potential of multiple doses of
      APX001 administered orally.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple oral doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG).</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple dose of APX001 as measured by area under the curve (AUC).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by terminal half life (t1/2).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by accumulation ratio.</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1a, Period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose, crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a, Period B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose, crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a, Period C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a, Period D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose, crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b, Period E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose under fasted conditions, crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b, Period F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose under fed conditions, crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses in presence of CYP probe substrates</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single IV dose</intervention_name>
    <arm_group_label>Cohort 1a, Period A</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single oral dose 1</intervention_name>
    <arm_group_label>Cohort 1a, Period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single oral dose 2</intervention_name>
    <arm_group_label>Cohort 1a, Period C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single oral dose 3</intervention_name>
    <arm_group_label>Cohort 1a, Period D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single oral dose fasted</intervention_name>
    <arm_group_label>Cohort 1b, Period E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single oral dose fed</intervention_name>
    <arm_group_label>Cohort 1b, Period F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple oral doses 1</intervention_name>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple oral doses 2</intervention_name>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple oral doses 3</intervention_name>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytochrome P450 substrates</intervention_name>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo control</intervention_name>
    <arm_group_label>Cohort 1a, Period A</arm_group_label>
    <arm_group_label>Cohort 1a, Period B</arm_group_label>
    <arm_group_label>Cohort 1a, Period C</arm_group_label>
    <arm_group_label>Cohort 1a, Period D</arm_group_label>
    <arm_group_label>Cohort 1b, Period E</arm_group_label>
    <arm_group_label>Cohort 1b, Period F</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of childbearing potential must agree to avoid pregnancy during the study and to
             use contraception at least 2 weeks before the start of the study until 3 months after
             the last dose of study drug.

          -  Males with partner(s) of childbearing potential must agree to use appropriate barrier
             contraception from the screening period until 3 months after the last dose of study
             drug.

          -  Screening hematology, clinical chemistry, coagulation and urinalysis consistent with
             overall good health.

          -  No significantly abnormal findings on physical examination, ECG and vital signs.

          -  Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Any uncontrolled or active major systemic disease including, but not limited to:
             cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological,
             immunological, psychiatric, or neoplastic disorder with metastatic potential.

          -  History or presence of malignancy within the past year. Subjects who have been
             successfully treated with no recurrence of basal cell carcinoma of the skin or
             carcinoma in-situ of the cervix may be enrolled.

          -  Use of prescription medication within 14 days prior to the first dose of study drug
             and throughout the study.

          -  Use of non-prescription or over-the-counter medications within 7 days prior to the
             first dose of study drug and throughout the study.

          -  Positive results on any of the following Screening laboratory tests: serum pregnancy
             test, urine alcohol test, urine drugs of abuse, hepatitis B surface antigen, hepatitis
             C antibody, and human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Hodges, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amplyx Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

